Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

C B m E & U

C B m E & U artwork

Democracy in Bioethics with Lucy Frith

Mar 3, 202546 minAudio

Send us Fan Mail What, if any, is the role of the masses in deciding who gets which kidney? Why should the public be involved in these ethical dilemmas? Should the public get to decide whether bioethics researchers keep their jobs? In episode #3, Professor Lucy Frith (Centre for Social Ethics & Policy, University of Manchester) answers these questions with Sinead and James the role of the public in bioethics. Remember people, be savvy!

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_04The center presents a new podcast, C BME and You, a podcast devoted to promoting awareness and debate around controversial ethical issues in biomedicine.

SPEAKER_00Welcome back to CB Me and You, a podcast about biomedical ethics. Today we discuss public patient involvement in health research. Should the public be involved in saying what we should be researching, and what kind of shenanigans will occur when this happens? Joining us today is Lucy Frith, professor at the Center for Social Ethics and Policy at the University of Manchester. Welcome, Lucy.

unknownThank you.

SPEAKER_01We are so excited to have you here. We're gonna begin with our three favorite questions. Um, and given that you've just tried it for the first time, coffee or copy?

SPEAKER_02I think copy. Really? Yeah. That's a quick convert.

SPEAKER_01Yeah, it's nice and strong.

SPEAKER_00It just hits you in the face with the flavour.

SPEAKER_01Yeah, yeah. It has um sweetened condensed milk in it, which I adore. I think it's much better than sugar. Yeah, sugary sugar.

SPEAKER_00Yeah, because it's so much more powerful.

SPEAKER_01Mmm. What hits you in the face with the sugar?

unknownShh.

SPEAKER_01We don't need to hear about that.

SPEAKER_00Sorry, you just tried it. I should let you enjoy it properly. We're giving you the bad news. I know, mummy.

SPEAKER_01One time, one time um someone uh told me that you can't drink calories, like that's not how science works. And I'm here to pass on that information. UK, right. You you can't drink calories.

SPEAKER_02Well, as a baby, my mum used to give me carnation milk, which is a UK condensed brand of condensed milk, an egg white. Delicious. I say bring it back, no calories.

SPEAKER_00Like in the same drink?

SPEAKER_02I'm I don't think so, but child ruin practices have changed.

SPEAKER_01Sounds like a child's cocktail, you know, like get that egg foam. Condensed milk.

SPEAKER_00It sounds like something that they give you to get uh grabbing a hangover.

SPEAKER_01Yeah, actually.

SPEAKER_00And your condensed milk and egg white.

SPEAKER_01No, not together like egg white and then also one shot, one shot. Yeah, I'll assume.

SPEAKER_02I was a baby, I don't know. Probably well, I've got bad teeth.

SPEAKER_00Yeah, chaser of egg white.

SPEAKER_01Anyway, moving on to the next question. What country would you like to travel to the most next?

SPEAKER_02Um well, I'm going to Lisbon in a few weeks, so I'm gonna say Lisbon in Portugal. Oh, that's I'm looking forward to that.

SPEAKER_01Is it is it's winter there at the moment? Um, spring. Oh, beautiful. It looks in the colorful there. Yeah.

SPEAKER_02So you haven't been before? I have been before, but um we're staying at a very nice hotel, so I'm quite excited about that. Excellent.

SPEAKER_01So the hotel, not necessarily Lisbon. Well, both, I think.

SPEAKER_00Yeah, yeah, I do get excited about uh the possibility of staying in a nice hotel because most of the time when I travel, I'm staying in like budget hostels and stuff. Yeah, yeah. So when you do get the chance to stay in the nice hotel, you're like, well, well.

SPEAKER_01It doesn't leave. Where's the robe?

SPEAKER_02Yeah, I've been there done that. I'd only go to nice hotels in you.

SPEAKER_01Um our third and final question for this part. What song would you sing at karaoke?

SPEAKER_02Okay, well, I'm gonna be very cheesy and say, I will survive. Excellent.

SPEAKER_00Yeah, that's not cheesy at all.

SPEAKER_02End of night song, I think. When you've um had more horrible drinks, you've bedded into the experience. And then you go home and cry and they'll cry.

SPEAKER_00And next day you're like, oh, I hope my never friends never see me again.

SPEAKER_01You get an unsolicited clip of you singing it, and you're like, I really thought I hit that note.

SPEAKER_02No, with no expectation of hitting any notes at all.

SPEAKER_00I think that's the best thing to do, to go in with no expectations.

SPEAKER_02100%.

SPEAKER_00Okay, serious questions. Now, the first question is your basic what is this kind of question. So when when I think of public involvement in health research, I almost imagine a panel of randoms just deciding whether we should fun uh fun cancer research or not. And that that worries me, a panel of randoms deciding my future. So could you tell us a little bit more about what is public patient involvement in health research and what you have in mind to talk about that?

SPEAKER_02Okay, well, I think that's a good question because it's lots of things. So that I think I think it can be a panel of people deciding on what we should fund in terms of research. So in the UK, um the National Institute of Clinical Excellence did have some citizens' panels that did decide on um helped people make decisions on what drugs should be prescribed and the evidence and so on. But it can also be at the level of the research project.

SPEAKER_02So, in a way, it can be anything from very high-level policy right down to involvement in a specific clinical trial or specific research project. So it's a very, very broad area. So I think that's the first thing I think I was trying to stress in my talk was that when we talk about public involvement, we can mean all sorts of different things in different situations. So it's really important to be clear about exactly what kind of thing we're talking about, and then different criticisms might pertain to different situations and different justifications.

SPEAKER_01So we've got my in straight in my my brain, I was like, oh, clinical trials. Of course, we need the public for these sorts of things. And then you just said that we had uh the public advising on whether or not we should prescribe certain drugs um based on evidence. Um and it sounds like a like a jury. And are they are they qualified to be making these decisions? Like how when when you're talking about that policy level, how informed are they?

SPEAKER_02Well, that's a that's an interesting point, but of course, juries are meant to be um the classic. Um now I'm in a law department and getting involved in sort of reading the law and things. There's a lot of reasonable men in law, you know. You've hear the reasonable man on the Clapham omnibus, and you know, it's very I'm sure they mean person, but or maybe they didn't. But but in a way, a jury is meant to be a reasonable person who has no particular dog in the fight, if you like, an impartial panel of people who will listen to the evidence and weigh up if someone's guilty.

SPEAKER_02So you don't pick criminal juries or juries in trials for expertise. I mean, and that's one of the problems of very complicated financial trials, for example. You know, juries aren't expert, uh might get a bit lost. So I think the idea is um with citizens' juries at that level of policy, is that they are the person in the street and you educate, you present evidence to them and they help weigh it up. And they may be part of the decision-making process, not the whole decision-making process.

SPEAKER_02So they may be part of the things that the committee will ultimately bring to bear on the decision.

SPEAKER_00Okay, so in your research on uh this kind of public patient involvement, um I guess part of it is to try to disambiguate and clarify these different issues and the different ways in which the public uh can get involved. Um Do you have a particular dog in this race? Do you have like uh an opinion on like, okay, we we based on my research, these are the ones that we want to focus on, and these are the good ones, and there are there's some others that are a little harder to get going.

SPEAKER_02Um I think yes and no. I think there's a lot of good arguments of why we might want people involved at policy level, just generally, you know, democratic presumptions in society that we think we should involve people. Um, but then it's a very different beast at the level of, let's say, for sake of argument, a clinical trial, where you might have more patients than public. So the people who are involved might be people who are you know affected by the condition you're studying or in the situation you're trying to unpack.

SPEAKER_02And then there might be different kinds of imperatives like them bringing their expertise and helping you as the researcher understand the condition more. So I think it's it's working out where it's appropriate and also and within where you know, and within that individual setup, how you organise it so that I think you get a balance of opinions that you don't swing too much in one direction or the other. So it's so I think traditionally we, you know, health medical research has been very hierarchical, you know, highly weighted on expertise.

SPEAKER_02I mean, if you think about the rise of evidence-based medicine, you know, we've moved from sort of clinical considered opinion of what the consultant said and had always done to trying to think about employing research in practice. So, in a way, that's almost a form of opening up clinical decision making. Um, so you might think it's a good thing that we move away from just thinking about what medics might be interested in, scientists might be interested in, and also trying to bring in what patients might be interested in.

SPEAKER_02Because I think with research, there's a lot of um, and so you get this in bioethics research, there's certain topics that are really interesting philosophically, say, like about the status of the fetus. I mean, for the JME, we get loads of articles about that because it's an interesting philosophical topic, you know, the ontological, all that. But practically, there's probably not a lot, you know, whereas there's other topics that are much more practically important but much less philosophically interesting.

SPEAKER_02So it depends what you're trying to do the research for. And I'm not saying either one is better or worse, it's just that you might be motivated to say something important philosophically, and that would be one kind of study, or you might be motivated to make a big practical difference, say, with abortion care, and that probably wouldn't be talking about the status of the fetus. You might want to look at support services and have women access them and so on. So you might say that's true with medical research, that rather than thinking what's scientifically interesting, um, although you know, with clinical research, maybe we need to focus more on what in people experiencing healthcare actually need and want rather than what scientists might think is is interesting.

SPEAKER_02And they might pull in. They don't always, but they could pull in different directions.

SPEAKER_00Yeah, so in in any given case, I guess there are there are a few different I guess levers that we can pull on that change that will change uh the nature of the kind of uh you know citizen panel or or public patient involvement. You know, as you mentioned, it can differ at the kind of level of uh where of discussion, I guess. You know, you could imagine panels on like every single uh research uh of panel and or whether every single ethical panel deciding whether things something should be funded or not.

SPEAKER_00Or it could be at a higher level and a a more general, should we fund this kind of research in general? Um and then another lever is like who we're getting on the panel. Uh you know, it could it is it patients, patients and their families, or you know, random people in the street. Uh these random people again.

SPEAKER_02Yeah.

SPEAKER_00I I love the random people. Um so I'm wondering if you could like paint a bit of a an execution example to paint a picture of how we might decide in a given situation, uh how we should adjust these different uh Yeah, I think well that there's an interesting question about who who we get to involve um per se.

SPEAKER_02I think at the level of I mean in the UK in England there is a statutory requirement that healthcare bodies take, involve the public in some way to get feedback, quite how much that's done and how rigorously is a different kettle of fish. But there's a sense that that's a good thing to do, that you you um I mean the NHS has always grappled with this, trying to be, even though English, I mean the English is the English NHS, not UK, um, struggle with being either a national or a very regional organisation and it's flip-flopped over the years.

SPEAKER_02But and that the idea of having these regional sort of commissioning bodies is that you're responsive to your local community. So if you have a very ethnically diverse community, you tailor your services. If you have a very old community, you'd be wanting different kinds of services. So I think in one level you could say the NHS has always tried to involve the public in some way in how it distributes or what it commissions at quite a broad level.

SPEAKER_02Um, I think recently in research we've seen the rise of patients involved in specific research projects. Um, they're also involved on grant panels. So for an NIHR, you often have a public uh contributor on the research panel, and they'll they'll give you a the public contributor review you get. So you get five or six reviews from the academics, they've asked to review it, and then the public contributor reviewer.

SPEAKER_02So that for the NIHR that's how they distribute funding, so that's very embedded. And then at the project level, you might, depending on your project, get some people from who might you see as aiming to speak for the people with if you're doing a trial on asthma, you might want people who are asthma sufferers or carers of asthma sufferers or carers and so on. So so I don't quite sure if that answers your question. But there's I I think because there's all these different levels and different ways you can involve broadly these lay people, it is quite hard to pin down.

SPEAKER_01I would like to just play devil's advocate for a second. And this is a position new to me. This is usually James's job to be devil's advocate.

SPEAKER_00Well, I'm almost so friendly. Every single guess, I'm like, no, you're completely right. No more questions.

SPEAKER_01You've convinced me, I have no further questions. So just um one concern that someone might have about public involvement and and is this idea that experts alone are not charged with making value-laden decisions. So that's a quote from your excellent paper, which I enjoyed. Um, and I I just want to ask, is that is that for the best? If if we are taking a space away from an expert who has been trained in that particular field, who knows that literature back to front, who has dedicated their life to doing making these sorts of decisions, what can involving the public add to these really controversial and difficult decisions?

SPEAKER_02Well, I suppose the argument would be there that no one is be careful what I say now, no one is an expert in the values, in a sense. I mean, obviously, as bioethicists, we like to think we are. Um I'll just find from our job now.

SPEAKER_00Don't make us lose our jobs now.

SPEAKER_02But I suppose, in a sense, although we might be experts in one way of thinking about values, it doesn't mean that our moral opinion is any better than anyone else's. So if we went to the 7-Eleven um and got the eight people standing in there, seems to be a reasonable number of people standing that 7-Eleven regularly. Um we seem to pack. Um, and we got them in here. There'd be no, I don't think there'd be it would be reasonable to suggest that we were more, you know, that our our views on values were any better than theirs.

SPEAKER_02We might be able to articulate them and talk about Plato and Mill or whoever we wanted to talk about. But ultimately you might say, well, their value judgments are just as valid as ours. We're not we don't have any particular, arguably, I mean there is different views of ethical expertise, but you could say we don't we don't have a privileged position, we're not those sort of priests, if you like, here to say this is right and therefore you should follow us.

SPEAKER_02So I suppose in that sense you could quite easily make an argument that values are one thing, but medical expertise is another. So while the doctor might know about the evidence for a particular treatment, they might not know if that's the right treatment for that person in that situation or for society, for instance. So, what I'm doing in Lisbon is talking about germline therapy. So I'm going after someone who's a scientist, an expert in this, and does embryo gene editing.

SPEAKER_02Now, obviously, they know loads more about well, they could probably do it, I couldn't do it. But I don't think just because they have the tech well, and that's because they know they they're a scientist involved in that, they have any greater or lesser appreciation of the ethics than you or I do. So, in that sense, I'm a lay person because I'm not a scientist, but I think I can contribute to discussing the values if they explain the science to me. And you could always explain in broad brushes the science to people, I think.

SPEAKER_02But that takes time and is often difficult, but I think you can do it. I think it's quite easy to go, people won't understand, but people make lots of complicated decisions all the time, and we and also we, you know, some people might think it are happy to trust professionals with that, and that's also okay.

SPEAKER_00You say we're not priests, but the gown that I wore for my graduation disagrees with that. I felt very priestly. It looks very priestly.

SPEAKER_02True, true. Yeah, they can do it. Is it red?

SPEAKER_00Uh it had a it was black with a blue thingy. I don't even know the names of the of those things. Um a Robin Hood. Yeah, well, let's just call it a cape because that sounds cool. Okay.

SPEAKER_01So so bringing back what you were saying is that the public does have moral standing. Um, you know, in in law we talk about who has standing to be involved in a particular decision, and those outside that who don't have standing, well, they have no right to bring this matter before a court of law. And so what you are saying is that in matters of particularly public health, in uh in which we are all impacted by these decisions and in which we all have experience in making controversial and ethical decisions, the public does have moral standing and should be included. Do you think there are limits to this?

SPEAKER_02Um I think there are practical limits. I mean, I suppose it's where you where you sort of draw draw the levels, isn't it? Because arguably you could say, say in the UK, we've had an election relatively recently, parties talked about the NHS. You could say at one level people vote for the kind of health system they want. Obviously, that's one bit of many decisions you make when voting for a political party.

SPEAKER_02So you could say a party, you know, that there's a sort of democratic buy-in to that kind of position on the NHS from the government because that's I mean, that has to be the democratic process. Um now you can argue that it's not because lots of people don't vote. Um it's one issue amongst many, but but in a way, that is how sort of a Western liberal democracy works. You have to sort of can't faffle about too much with that.

SPEAKER_02But I suppose it's so, for instance, the Human Fertilisation and Embryology Authority, which deals with things like embryo editing and reproductive technologies, they've had various public consultations over the years since they were established in 91. And so for when they did the mitochondrial DNA transfer consultation, they they went round the country, they did open meetings, they talked to people, they organized events, and you get I mean, but you don't get a huge buy-in.

SPEAKER_02I mean, one public consultation they had got 200 responses. Well, that's from a nation of I don't know how many people live in Britain, 60 million?

SPEAKER_00Roughly at least three.

SPEAKER_02At least, yeah. So that's not a lot of people, is it? Responding, you know, 200 people, that's a teeny tiny number. So you can say, well, but at least they've been asked. In fact, they did, they went, oh, I couldn't care. Is um that's fine, in a way you can't force people to be involved. And quite often um, you know, when the NHS regularly sends out surveys and people don't answer them, and and you know, with student evaluations, you send out students and they don't bother replying, and partly is you think, well, that must mean you're reasonably happy.

SPEAKER_02Or maybe not. But you know, you can't force people to engage. Sometimes people don't want to be doing it. So I think it's the levels of that. So I think I don't think we're in danger of a sort of populist overwhelm of medical expertise. Because I don't think there's enough people with sufficient passion about it to be involved in a lot of things. But then on the other hand, there are issues like abortion where you do see a huge popularist. I mean, that's not medical research, although people do object to medical research on embryos and so on.

SPEAKER_02So I think it depends on the issue, but I think generally we're not at a kind of overwhelm of the public.

SPEAKER_01My next question was gonna be um well about that idea that simply because the majority of people think it's a good idea doesn't mean it is a good idea. But your your practical response to that is well, I just don't think a majority are responding, so that's not really an issue.

SPEAKER_00But this does make me realize I just thought of this, like it does make me realize that this might be a bit make it vulnerable a little bit to certain kinds of like sudden takeovers by by certain kinds of special interest groups or minorities. Uh I can't think of any specific uh cases right now, but uh I'm pretty sure I've seen it well now and then. Uh you know, you have like some some some kind of uh case or some kind of issue that we've been working on for a very long time. Um and you know academics or professionals have kind of been working on it with uh with no issue, and you know, there's some kind of access to uh public access to it, but nobody really cares.

SPEAKER_00And then some group somewhere realizes hey, we can actually really change things by by taking over, and suddenly they come in in a in a drove and just you know mess the whole thing up or you know by their lights, change it for the better.

SPEAKER_01So hearing some judgment here.

SPEAKER_00Uh there is. Uh yeah, so so yeah. So how yeah, it seems to me that what you're proposing does leave that kind of vulnerability.

SPEAKER_02I think I wouldn't deny that. I think you're right. And there have been cases of I mean, particularly around the the nice deliberations, because there was a special cancer fund for for very expensive cancer drugs was set up quite a while ago now. Um, and my colleague Rachel Baker, who's a health economist, did some really interesting work about priority setting around that. Um, and of course, say at the level of say NICE's deliberations about certain drugs, there were very vocal patient groups, particularly, I mean, this is going back a lot, you know, like 20 odd years, but a drug for multiple sclerosis, the the patient association was very much lobbying and pushing for a particular drug, I can't remember what it was.

SPEAKER_02And this patient group was funded by the drug company who produced the drug. So, and some patient groups with conditions that are you know have amenable to very expensive drugs, you know, are often supported by drug companies, and therefore you could say, is that that becomes a sort of pressure group who are campaigning for these um certain drugs, and that seems to be a case where that that seems to step beyond that idea of involving the the layperson, you suddenly get these quite big pressure groups, and they might have a disproportionate influence.

SPEAKER_02But I think um with those things, I mean, in the nicest in in nicer's setup, it was always one part of the equation, and I think that's having the balance that you take it as a whole, that one element is not going to overwhelm the whole decision-making process. So you might take, you know, a very simple example, you manage to get everyone in the UK and they vote for something, like they have a referendum. I mean, they the Irish did, didn't they, on abortion a few years ago.

SPEAKER_02Um, and you get a I mean, like Brexit, you could say you take a referendum, you get the wrong decision, and you might think um we're going to ignore that. Although that's quite hard one. I mean, Switzerland does this, has a lot of referendums on quite on issues that are quite granular. Um so I mean I think in my lifetime there's only been one referendum in the UK, and that was on Europe. You know, we don't have referendums on medical research, but but have a look at Switzerland, because I I can't remember any examples, but they do have quite granular referendums and they ask everybody on particular topics.

SPEAKER_02But I think I think if you have it as part of a part of the decision making, then you do have some checks and balances, that it's not just well, the public think this. And you're right, you need to decide where you want to bring in democracy, because we did with the referendum on Europe. Um, but you might not on other things.

SPEAKER_01So you think it's both important to involve the the public for the idea that while you were involved in this decision, it's a democracy. We considered your opinion, and maybe that in that in itself satisfies certain portions of the public because they felt included. Even if they're not happy with the outcome, they were at least involved. Yeah. But then surely it's not just like a tokenistic, you know, oh, we involved you, but we're gonna ignore everything that you said, even though sometimes it might be necessary, particularly if you do have those extremely passionate, disproportionate, radicalized groups.

SPEAKER_01But all in all, is there research that shows that involving like uh the public in these sorts of decisions actually improves healthcare outcomes or or has other practical consequences?

SPEAKER_02Well, at the level of research studies, there is there is some evidence that it does improve research outcomes and it improves uptake of the research findings and so on, and improves dissemination, yeah. I mean at a policy level, I mean there have been consultations, the British, the government did, and you know, the public, well, the tiny little bit of the public um who responded were for something and it was completely ignored and they changed the law anyway.

SPEAKER_02So I think it's always Parliament at big, you know, the level of legislative change will always take that, take the decision, even in the face of having these small consultations. But I think I think it's there's all these different levels. So at big policy decisions, that's one kind of set of considerations, and then at the level of research studies, there's very different ones. So you might want to, for just practical reasons, have a lay group where you're you know making suggestions for how things might work, getting their feedback, seeing what symptoms are most troubling to them, you know, having a sense of the lived experience of the condition that can help you develop the treatment or the drug and make it more responsive to the needs of the community.

SPEAKER_01It seems like the more narrow the healthcare research topic, the greater incentive there would be to involve public involvement because the advice they provide will be so much more granular and specific and outcome-oriented. But then, as you were saying, when you have those big moral philosophical questions of, you know, should we permit abortion, should we not permit abortion, is that always gonna be useful, particularly in pluralist societies where you can just have permissive rather than like mandatory or prohibitive legislation? Uh like do you have any comment about that?

SPEAKER_02Um I suppose with those big big issues, yeah. I suppose I mean in the UK the law does, you know, for certain things tries to let, you know, like with abortion allows you to make your own decision about that within certain limits up to um 24 weeks, I think. Is it? I don't know. I haven't checked in a lot. Yeah. Um but you know, within pretty broad parameters and the exception, you know, and the accepting that if you don't want to be involved in that, we have a conscientious objection clause.

SPEAKER_02So if you're a healthcare professional, you don't have to work in those services. Obviously, as an individual, you don't have to have one. Um, so it's seen as if that's something you can make your own moral decisions about. But obviously, that's a moral decision in itself, because we don't allow you to make your own moral decision about murdering people. So that's obviously already a There are limits, people. Well, that's already putting it in a category of well, like, you know, you can do that if you wish or not. So that's already saying the state will allow that and leave it up to individual conscience.

SPEAKER_02So I suppose for those really big moral decisions, you would be thinking about, like, for instance, the assisted dying bill is going through parliament now, and that's being debated. Um, there hasn't been a referendum, but it's gone through the sort of parliamentary process. People can submit evidence. Um, they're looking, you know, and they're taking evidence from patient groups and all sorts of different and academics. One of my colleagues has just been at parliament talking to them about her research.

SPEAKER_02So that becomes, I suppose, that sort of a f almost, you know, that parliamentary deliberative process where you can lobby your MP. I mean, that I mean that's just kind of uh, you know, a work that sort of democracy, you know, it might you might be having the same debate about well, the runway, you know, the government want a new runway at Heathrow and a similar, probably more, you know, when you you will start saying, Do people want that? Is that something we want as a society to encourage air travel?

SPEAKER_02So I think at that level, those are there's quite well-worn paths for involving people, and there are dangers, but then as Winston Churchill said, you know, democracy is not a great system, but it is the best one there is, you know, it's not perfect, there's a lot of problems, but it is that generally better than um anything else. But at the level of research studies, you might say, is that the kind of area where we should even be trying to have some democratic imperative? Because we've got our medical experts, we've got all the trialists, the stats people, you know, what what are those lay people actually bringing?

SPEAKER_01Yeah, I I agree with you. I think that the involvement of the public in certain ethical controversial decisions in healthcare is can really be um a great way to just get through the decision that we have to make. And I think sometimes we like to sit in our chairs in this office and just chat about, oh, this is a great idea, oh, this is a great idea. But at the end of the day, a decision has to be made, healthcare has to be provided or it has to not be provided. So I like that idea of using the public as a way to gauge where most people sit on a particular spectrum, and like the closer you have to get like a really strong disagreement, like such as you know, 50-50 between pro and anti-abortion, well, then that's when we know we need permissive legislation.

SPEAKER_01But then if you have a really strong consensus on a particular issue, that's also really helpful. And I think that, yeah, we shouldn't uh, you know, gatekeep these ethical decisions from the people who are honestly most affected by them. But yeah, so I I I've been pushing you with some questions during this podcast, but I actually agree with you.

SPEAKER_00Really playing the devil's advocate there.

SPEAKER_01I'm really proud of myself. I learned a new skill. XP unlocked.

SPEAKER_00So you mentioned a bit earlier that uh one issue is that many people don't attend these things. And short of probably making it compulsory, a lot of people will never attend these things unless they're the kinds of issues that really animate people and really get them going, like uh like abortion or something like that. And even then you might only get like if you were to do a referendum referendum on abortion, you might get 40 or 50 percent of the above. Uh and I suspect that in many of these cases, uh the representation might be a little disproportionate.

SPEAKER_00Uh you might have a lot of people who have more time on their hands or who are more tuned into these issues, uh, and often this leaves out um people who are minorities and uh people of like lowest social economic statuses. So is there some way to remedy uh and address these issues?

SPEAKER_02Yeah, no, that's a great question. And I think I presented an example, I think one of your questions was about examples that I was involved in a big NIHR infrastructure grant, um, and we had it was for very applied research, um, but but medical, sort of clinical, but applied. Um, and we had a group of public advisors who were on the management committee of the grant, were very involved in all the decision-making structures, and they were a group of people who were very diverse.

SPEAKER_02Um, we'd made me and my predecessor and the team, it wasn't just me, um, you know, made a great effort to recruit people, um, bring them on board, nurture them, say train them, but but support them in being able to work with us on the grant. And I think and I think that takes a lot of work, but I think it is possible because one of the criticisms is you know, in a UK context, you tend to get lots of middle-class white retired professionals who are articulate, able, you know, financially independent because they've retired on in the days when professionals have good pensions.

SPEAKER_02Obviously, that will change as we go forward. What was that? Looking forward to everything. Yeah, but at the the retirees at the moment, um, you know, so you get, you know, the sort of classic school teacher, you know, people who are, and therefore, um you're not getting a diverse group, and in a way, you're almost getting people very much like the researchers, so you're not kind of broadening that epistemic pool. It's just kind of more of the same, but just a bit older.

SPEAKER_02Um, and and I think there is a there is a tension in that because obviously is as you said earlier, you need to people need to know enough to make be able to make comments about things. Because if you know nothing about something, you can't really make useful critiques, can you? If you were, you know, if you were gonna, if I gave you a bio, I mean, if you're biochemist experts, apologies, but a scientific subject you know nothing about and said, here's a journal article, review that for me.

SPEAKER_02You know, I wouldn't be able to comment intelligently on a biochemistry paper because I don't know enough about it. Well, I don't know anything about it, so what's you know, you could ask me, but so it's you need to give people enough knowledge, but then the criticism is then they become experts, so you're losing their raw, sort of raw leanness. But I uh that's not a word but the umami, yeah, the walking. Yeah, that thing we want, you know, that kind of thing we want to get out of them, and and I think there's an element of truth in that, but then on the other hand, with the arc, because we had that was the project, we had so many people, and and they did become kind of experts in this form of participation, but that did enable them to have a make a big contribution.

SPEAKER_02But again, it was I think there was a balance of they were what they were part of the team, not I think sometimes you can get in any group dominant people who tend to drive the decisions, and I think if you try and have a where everyone can put their decision in is valued and heard, I think if you have if it swings too far one way or the other, to you know, because I I have been in meetings with very dominant clinicians.

SPEAKER_01Um I know who the So many words were unspoken just then.

SPEAKER_00Ah man, I wish the the the the viewers could sometimes see a video of us talking.

SPEAKER_02Yeah.

SPEAKER_00You should have seen the look on Lucy's face just then.

SPEAKER_02It's like so that was a go figure look. But um, so you know, but obviously but I've also been in situations where there means very dominant public contributors and you feel that they're railroading people. And so I suppose, I mean, one of the themes in my work, I suppose, is that it's important to think about process. Process is very important and does a really important job in decision making, it's not just um a sort of administrative nicety. That good process does produce better ethical decisions, and I won't really have time to justify that claim, but we'll take you for it.

SPEAKER_02Yeah, just just we'll just accept it. There's a lot of literature on it um that I I mention in various things I've written. So I think it's important that you have that. I mean, I was on um an NHS priority setting committee, and the person who chaired that, Nick Partridge, was the most amazing chair I've ever, Sir Nick Partridge, I think he is, I've ever come across. And he was someone who could bring everyone, pick out the views, bring it all together, summarize it, and and really you felt at the end of it that the group had made the decision, didn't allow one person or one group of people to dominate.

SPEAKER_02So I think in an ideal sense, any kind of decision that has that tries to reach some form of not not consensus because you might not get agreement, but the agreement to do what we're doing, recognising that not everyone might be on board with it.

SPEAKER_00I would follow a Sir Partridge. Because the sound of it is I'm Sir Partridge. Oh, you know what? I'll follow you to battle, sir Partridge. So the yeah, the the idea of you brought up so that you brought up the idea of like how we need to educate people sometimes. You bring as many people in, uh even those who don't really know about the issue and are not really uh educated in it or s themselves, and try to educate them. And and this does leaves us quite a lot of power, I guess, in in the hands of the person doing the educating, because sometimes the the the decisions on how to educate uh are also not value neutral and there are also a lot of issues.

SPEAKER_00You know, you can try to uh for example, if you give them the information the best that you know how, uh on one it might look like you you're leading them in a certain direction. Uh and on the other hand, if you try to give a a so-called balanced description of the issues, uh that has its own issues. Uh so for example, I was in Australia a couple of years ago when there there was a certain referendum on an issue, and the government sent out a whole bunch of like little booklets on like reasons to vote yes or reasons to vote no. Okay. I was looking at it uh and and thinking, well, these reasons are not the same.

SPEAKER_00You know, there are some reasons here which are clearly better than others. So I guess yeah, there are a whole bunch of issues in trying to educate people uh uh on how to uh how to think about an issue. Um and I'm wondering if there are ways to do that in better or more neutral ways.

SPEAKER_02Um arguably I suppose you can never really be neutral, can you, with information giving. I think I mean citizens' juries are set up to try and give the pros and cons, but so but um I don't think you'd probably ever be able to say that's completely unbiased because ways of putting things. But I think in research projects it's more it's more just giving them enough so that they can assess things themselves and come to their own opinions.

SPEAKER_02It's not I mean, and it's not always about making big decisions, it's just having input and and giving a bit more context or explaining why why they think you know a certain treatment regime wouldn't work, for instance. And you know, there's a great history of you know, do gooders doing things for people less fortunate than them that the people didn't want or didn't need or couldn't use. Um, so I think involving people in in decisions about them can help the things you're trying to develop be more applicable for them.

SPEAKER_02So it might simply be saying, Well, I mean, one of the things, you know, with COVID when we were trying to involve people was really simple things like not everyone had a laptop or a computer. And you know, as an academic, I've you know lots of people access information just on their phone. Now that's not rocket science, and I'm not claiming that's but actually them saying, you know, uh don't give me all these PDFs because I find them really hard to read on my phone, and making sure all our documents were optimised for mobile phones, meant they could actually read them properly.

SPEAKER_02And that's something you know, those terrible, I mean, in unaccessible PDFs in columns that people give out and journal articles formatted like that that you shouldn't do anymore because it's inaccessible. It it's very hard to read that on a mobile phone. Now a lot of um professionals don't only access comic content on mobile phones, but a lot of other people don't have a laptop, so that's that's not particularly profound, but that stops someone reading something easily.

SPEAKER_01I think that we do not have time for more today. I know that you uh are a very busy person. I think that to summarise, I really like you quoting Winston Churchill for many reasons, but I like that idea that you know, democrats, it's not a perfect solution, but it's the best we've got. Um, and I'm I'm happy with the defense of that.

SPEAKER_02I think we have to be pragmatic. I think if you when you start saying yes, there'll be bias, yes, some yes, there'll be interest, yes, there'll be things won't be perfect, but we we have to do what we can with the resources we can, and sometimes something is better than nothing, and at least if we and I think that's what I was saying at the end of the paper was at least if we're trying to move in a certain direction, we might never get to that golden point because you know we've been having democratic elections.

SPEAKER_02Well, not actually that long, anyway from that. Because women didn't get the vote till after the first world war. So so arguably not that long, in fact, but for you know, a reasonable amount of time. I mean, it's not perfect, but you'll try. Well, I'd like to say we are trying to move in direction, although globally we seem not to be, but that's a different kind of doing our best.

SPEAKER_01Yeah. Anyway, thank you very much for coming on the pod today. Well, thank you. Um, we look forward to your talk next week on a different topic. On a different topic, and take care. Thank you.

SPEAKER_04Thanks for listening to our new podcast. Subscribe online and tune in every first of the month. In the meantime, listen to CBME and U and be savvy.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Can Nihilism Improve Your Mental Wellbeing?

    Nov 2, 202645 minAudio

    Send us Fan Mail We spend much of our lives searching for meaning. Some of us look for it at work. Some in our families and friends. Some look for it at an overpriced spiritual retreat in Bali where some dude named...

    Credit the people on this episode

  2. Insurance Discrimination: Is it Fair? with Harisan Nasir

    Sep 24, 202649 minAudio

    Send us Fan Mail In some insurance scheme, you might be required to pay more because you are more prone to disability. In another, you may have to pay more because you're a woman (and are statistically likely to live...

    Credit the people on this episode

  3. Genomic Newborn Screening: Where less really is sometimes more with Ainsley Newson

    Aug 25, 202655 minAudio

    Send us Fan Mail Did you know that genomic sequencing can now screen newborns for hundreds of rare conditions right at birth? That looking too closely at our DNA might actually cause more anxiety than answers? And is...

    Credit the people on this episode

  4. The Hidden Side of Birth: Injury, Trauma, and PTSD with Angela Ballantyne

    Jul 2, 202648 minAudio

    Send us Fan Mail Did you know that over 80% of people who give birth experience an injury? That anywhere between 30 and 50% of people who give birth find it traumatic? And that up to 15% of people experience PTSD from...

    Credit the people on this episode

  5. Brains in Jars with Insoo Hyun

    Jun 1, 202656 minAudio

    Send us Fan Mail Could a blob of cells in a petri dish one day think? Feel? Have rights? In this episode, Professor Insoo Hyun (Harvard Medical School, one of the world's leading experts on the ethics of stem cell and...

    Credit the people on this episode